/ /

  • linkedin
  • Increase Font
  • Sharebar

    PCSK9 Inhibitors: A 5-Question Quiz


    Answer: B. As an adjunct to diet and maximally tolerated statin therapy for adults with HeFH or with clinical ASCVD.

     The indications listed in option B are the only currently approved indications for use of alirocumab in the United States. Option A is incorrect as this agent is not recommended as an alternative to statin therapy in patients who have no history of statin intolerance – statins remain the first line therapy for hyperlipidemia.. In Europe, alirocumab is approved for use as a stand-alone agent for adult patients with primary hypercholesterolemia (HeFH and non-familial) or mixed dyslipidemia as an adjunct to diet:

    a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach their LDL-C goals with the maximally-tolerated statin, or

    b) alone or in combination with other lipid-lowring therapies for patients who are statin intolerant, or for whom a statin is contraindicated.

    Alirocumab is not yet approved in primary prevention populations (option C) unless there is clinical ASCVD or FH present.

    Question 4.

    Payal Kohli, MD
    Payal Kohli, MD, is an attending cardiologist for Kaiser Permanente in Denver, Colorado.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available